The evolving role of MRI in pulmonary sarcoidosis: Comparative analysis with PFTs and progression markers

Ian Griffin; Romulo Pasini; Borna Mehrad; Mohammad Al-Ani; Tan-Lucien Mohammed; Diana Gomez Manjarres; Divya Patel; Stephan Altmayer; Edson Marchiori; Bruno Hochhegger

doi:10.36141/svdld.v42i1.15304

Authors

Ian Griffin College of Medicine, University of Florida, Gainesville, FL, USA
Romulo Pasini Department of Radiology, University of Florida, Gainesville, FL, USA
Borna Mehrad Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA
Mohammad Al-Ani Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA
Tan-Lucien Mohammed Department of Radiology, University of Florida, Gainesville, FL, USA
Diana Gomez Manjarres Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA
Divya Patel Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA
Stephan Altmayer Stanford University, Palo Alto, CA, USA
Edson Marchiori Department of Radiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Bruno Hochhegger Department of Radiology, University of Florida, Gainesville, FL, USA

Keywords:

MRI, pulmonary sarcoidosis, PFTS, imaging biomarkers, chest x-ray, CT, disease progression, lung imaging, sarcoidosis biomarkers

Abstract

Background: Sarcoidosis is a systemic illness with unclear etiology that commonly affects the lungs and intrathoracic lymph nodes. Chest radiography, CT, and, more recently, MRI can be used for assessment, with bilateral hilar lymph node enlargement and interstitial lung disease being common observations.

Objectives: In adults diagnosed with pulmonary sarcoidosis, how do chest radiography, CT, and MRI compare in the assessment of disease progression?

Study Design and Methods: This is a prospective study of 77 adults diagnosed with pulmonary sarcoidosis. Each patient underwent pulmonary function testing, chest radiography, HRCT and MRI within a span of 90 days. Chest radiographs were scored using the Scadding stage classification system. HRCT and MRI were both scored using the Scleroderma Lung Study I system. Pulmonary function was re-assessed after 12 months, with progression of disease defined as worsening symptoms AND ≥5% reduction of forced vital capacity (FVC). Disease progression was used as the gold standard to calculate area under the curve (AUC) of the receiver operating characteristic plot for radiography, HRCT, and MRI.

Results: There is strong correlation between chest radiography and MRI (r=0.649, P < 0.001), and CT and MRI scores (r=0.851, P < 0.05). CT and MRI scores correlated with forced vital capacity (MRI: r =-0.584, P < 0.001; CT: r =-0.308, P = 0.049) and diffusing capacity of the lung for carbon monoxide (MRI: r =-0.564, P =0.004; CT r =-0.216, P = 0.017). AUCs for chest radiography, MRI and CT scores were 0.70 (0.49-0.85), 0.71 (0.42–0.85), and 0.68 (0.26–0.90), respectively. Multivariate regression analysis of CT and MRI scores demonstrated statistically significant prediction of progressive disease by both modalities.

Conclusion: MRI may be a viable alternative to HRCT in the assessment of lung parenchyma and disease progression in patients with pulmonary sarcoidosis.

References

Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26-e51. doi: 10.1164/rccm.202002-0251ST

Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest. 2003; 123(2): 406–412. doi:10.1378/chest.123.2.406

Balan A, Hoey E, Sheerin F, et al. Multi-technique imaging of sarcoidosis. Clinical Radiology. 2010; 65(9): 750–760. doi:10.1016/j.crad.2010.03.014

Lenner R, Schilero GJ, Padilla ML, et al. Sarcoidosis presenting in patients older than 50 years. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19(2):143-147. PMID: 12102610

Akira M, Kozuka T, Inoue Y, et al. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest. 2005; 127(1): 185–191. doi:10.1378/chest.127.1.185

Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in Sarcoidosis. Chest. 1997; 111(3): 623–631. doi:10.1378/chest.111.3.623

Greco FG, Spagnolo P, Muri M, et al. The value of chest radiograph and computed tomography in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2014 Jul. 10 PMID: 25078638

Criado E, Sánchez M, Ramírez J, et al. Pulmonary Sarcoidosis: Typical and atypical manifestations at high-resolution CT with pathologic correlation. RadioGraphics. 2010; 30(6): 1567–1586. doi:10.1148/rg.306105512

Souza CA. MRI of the chest: review of imaging strategies. Radiol Bras. 2015; 48(6): V-VI doi:10.1590/0100-3984.2015.48.6e1

Chung J, Little B, Forssen A, et al. Proton MRI in the evaluation of pulmonary sarcoidosis: Comparison to chest CT. European Journal of Radiology. 2013; 82(12): 2378–85. doi:10.1016/j.ejrad.2013.08.019

Kauczor H, Ley-Zaporozhan J, Ley S. Imaging of pulmonary pathologies: focus on magnetic resonance imaging. Proceedings of the American Thoracic Society. 2009; 6(5): 458–463. doi:10.1513/pats.200901-002AW

Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013; 10(4) :362-370. doi:10.1513/AnnalsATS.201303-069FR

Hatabu H, Ohno Y, Gefter WB, et al. Expanding applications of pulmonary MRI in the clinical evaluation of lung disorders: Fleischner Society position paper. Radiology. 2020; 297(2): 286-301. doi:10.1148/radiol.2020201138

Levy A, Hamzeh N, Maier LA. Is it time to scrap Scadding and adopt computed tomography for initial evaluation of sarcoidosis? F1000Res. 2018; 7(F1000 Faculty Rev): 600. doi:10.12688/f1000research.11068.1

Russo JJ, Nery PB, Ha AC, Healey JS, Juneau D, Rivard L, et al. Sensitivity and specificity of chest imaging for sarcoidosis screening in patients with cardiac presentations. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2019 Mar. 11 doi:10.36141/svdld.v36i1.6865

Müller NL, Mawson JB, Mathieson JR, et al. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology. 1989; 171(3): 613-618. doi:10.1148/radiology.171.3.2717730

American Thoracic Society. ATS statement: standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995; 152(3): 1107–1136. doi:10.1164/ajrccm.152.3.7663792

Hillerdal G, Nöu E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984; 130(1): 29-32. doi:10.1164/arrd.1984.130.1.29

Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008; 134(2): 358–367. doi:10.1378/chest.07-2444

Lonzetti L, Zanon M, Pacini GS, et al. Magnetic resonance imaging of interstitial lung diseases: a state-of-the-art review. Respir Med. 2019; 155:79–85. doi:10.1016/j.rmed.2019.07.006

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022; 205(9): e18-e47. doi:10.1164/rccm.202202-0399ST

Hochhegger B, Lonzetti L, Rubin A, et al. Chest MRI with CT in the assessment of interstitial lung disease progression in patients with systemic sclerosis. Rheumatology (Oxford). 2022;61(11):4420-4426 doi:10.1093/rheumatology/keac148

DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837–845. PMID: 3203132

Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021 Dec 16;58(6):2004079. doi:10.1183/13993003.04079-2020

Jeong YJ, Lynch DA, Rho JY, Hamzeh NY, Suh YJ. Computed Tomographic Scoring Systems in Sarcoidosis: Comparison With Cardiopulmonary Exercise Testing Parameters. J Thorac Imaging. 2016;31(2):104-110. doi:10.1097/RTI.0000000000000198

Inoue Y, Inui N, Hashimoto D, et al. Cumulative Incidence and Predictors of Progression in Corticosteroid-Naïve Patients with Sarcoidosis. PLoS One. 2015; 10(11):e0143371. doi:10.1371/journal.pone.0143371